| Filed On | Filing |
|---|---|
| 27 Oct 2026 | FORM S-1 |
| 27 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
This Addendum (this “Addendum”) to that certain Securities Purchase Agreement dated September 19, 2025 (the “Purchase Agreement”) is entered into as of October 22, 2026 (the “Effective Date”), by and among Endovia Health Sciences, Inc., ... |
| 23 Oct 2026 | FORM PRE 14A |
| 22 Oct 2026 | SCHEDULE 13G |
| 15 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On October 15, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into a letter agreement (the “Letter Agreement”) with C/M Capital Master Fund, LP (the “Investor”) pursuant to which parties agreed to amend that ... |
| 08 Oct 2026 | FORM DEFA14A |
| 06 Oct 2026 |
8-K: Unregistered Sales of Equity Securities
On September 30, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master Fund, ... |
| 05 Oct 2026 |
Proxy statement: annual meeting on November 20, 2026
say-on-pay vote |
| 05 Oct 2026 |
8-K: Regulation FD Disclosure
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway |
| 24 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR A... |
| 23 Sep 2026 | FORM PRE 14A |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure
Endovia Health Sciences Closes Initial $500,000 Financing to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways |
| 18 Sep 2026 | FORM PRE 14A |
| 31 Aug 2026 | 8-K: Regulation FD Disclosure |
| 28 Aug 2026 | FORM 424B3 |
| 28 Aug 2026 | 8-K: Unregistered Sales of Equity Securities |
| 26 Aug 2026 | 8-K: Entry into a Material Definitive Agreement |
| 25 Aug 2026 | 8-K: Regulation FD Disclosure |
| 24 Aug 2026 | EFFECT |
| 21 Aug 2026 | 8-K: Regulation FD Disclosure |
Loading...